Cardio Diagnostics Holdings Inc., a leader in AI-powered precision cardiovascular medicine, has announced that it has regained compliance with Nasdaq's minimum bid price requirement. The company received a notification letter from Nasdaq's Listing Qualifications Department confirming that its common stock's closing bid price traded above $1.00 per share from May 13 to May 27, 2025, following a 1:30 reverse stock split. This compliance ensures the continued listing of Cardio Diagnostics on The Nasdaq Capital Market, with Nasdaq considering the matter resolved.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。